CN111201246B - 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 - Google Patents

结合补体成分c5或血清白蛋白的多肽及其融合蛋白 Download PDF

Info

Publication number
CN111201246B
CN111201246B CN201880046102.3A CN201880046102A CN111201246B CN 111201246 B CN111201246 B CN 111201246B CN 201880046102 A CN201880046102 A CN 201880046102A CN 111201246 B CN111201246 B CN 111201246B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
engineered polypeptide
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880046102.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111201246A (zh
Inventor
布里奇特·帞菲
朱利安·钱德
尼米斯·基拉
道格拉斯·L·谢里登
赛达斯·金达尔
保罗·P·腾博尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority to CN202311281139.3A priority Critical patent/CN117327188A/zh
Priority to CN202311281093.5A priority patent/CN117327187A/zh
Publication of CN111201246A publication Critical patent/CN111201246A/zh
Application granted granted Critical
Publication of CN111201246B publication Critical patent/CN111201246B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201880046102.3A 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 Active CN111201246B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311281139.3A CN117327188A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN202311281093.5A CN117327187A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
US62/531,215 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311281139.3A Division CN117327188A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN202311281093.5A Division CN117327187A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Publications (2)

Publication Number Publication Date
CN111201246A CN111201246A (zh) 2020-05-26
CN111201246B true CN111201246B (zh) 2023-10-27

Family

ID=63036501

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880046102.3A Active CN111201246B (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN202311281093.5A Pending CN117327187A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN202311281139.3A Pending CN117327188A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202311281093.5A Pending CN117327187A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN202311281139.3A Pending CN117327188A (zh) 2017-07-11 2018-07-11 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Country Status (12)

Country Link
US (3) US11498960B2 (https=)
EP (1) EP3625265A1 (https=)
JP (3) JP7684803B2 (https=)
KR (3) KR20250099285A (https=)
CN (3) CN111201246B (https=)
AU (3) AU2018301412B2 (https=)
BR (1) BR112019028269A2 (https=)
CA (1) CA3067247A1 (https=)
CO (1) CO2020000369A2 (https=)
IL (3) IL271920B2 (https=)
MX (2) MX2024005946A (https=)
WO (1) WO2019014360A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
EP3956344A1 (en) * 2019-04-16 2022-02-23 University of Washington Amantadine binding protein
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
JP6961860B1 (ja) 2019-12-26 2021-11-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 補体ｃ５の発現を抑制する二本鎖リボ核酸を含む医薬組成物
JP7343618B2 (ja) 2020-01-17 2023-09-12 オリンパス株式会社 発光装置、および駆動装置
JP2023522208A (ja) 2020-04-16 2023-05-29 アシスタンス ピュブリック－オピト ド パリ ウイルスによって引き起こされる補体媒介性障害を処置する方法
KR20230084210A (ko) * 2020-10-05 2023-06-12 알렉시온 파마슈티칼스, 인코포레이티드 피부근염을 치료하는 방법
TW202417490A (zh) * 2022-08-31 2024-05-01 美商艾力克森製藥公司 用於治療鐮狀細胞病的融合多肽之劑量及投與
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用
CN121518561A (zh) * 2025-12-24 2026-02-13 北京林业大学 一种PagRAP2.3蛋白点突变及其在植物愈伤再生中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151526A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2011095545A1 (en) * 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
AU2012254935A1 (en) * 2004-02-12 2012-12-06 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
CN103003301A (zh) * 2010-05-03 2013-03-27 百时美施贵宝公司 血清白蛋白结合分子

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
BRPI0617688A2 (pt) * 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US8435512B2 (en) 2008-03-03 2013-05-07 Novelmed Therapeutics, Inc. Anti-properdin antibodies
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
AU2011224224B2 (en) 2010-03-10 2015-07-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
MX2013000314A (es) 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
CN104114187A (zh) 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
EP2904014A4 (en) 2012-10-04 2016-09-28 Novelmed Therapeutics Inc FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
CN105658228B (zh) 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CN118184777A (zh) 2017-01-30 2024-06-14 亚力兄制药公司 单价抗备解素抗体及抗体片段
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012254935A1 (en) * 2004-02-12 2012-12-06 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
WO2010151526A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2011095545A1 (en) * 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CN103003301A (zh) * 2010-05-03 2013-03-27 百时美施贵宝公司 血清白蛋白结合分子

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria;Rother R P ET AL;《Nature Biotechnology》;第25卷(第11期);1256-1264 *
General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold;Cécile Vincke等;《JBC》;第284卷(第284期);3273-3284 *
Generation and production of engineered antibodies;Kipriyanov Sergey M et al;《Molecular Biotechnology》;第26卷(第1期);39-60 *
Selection and identification of single domain antibody fragments from camel heavy-chain antibodies;M Arbabi Ghahroudi el al;《FEBS Letters》;第414卷(第3期);521-526 *
The clinical potential of affibody-based inhibitors of C5 for therapeutic complement disruption;Berglund Margnus M et al;《Expert review of proteomics》;第13卷(第3期);241-243 *
The preclinical pharmacology of the high affinity anti-IL6R nanobody? Alx-0061 supports its arthritis;Maarten Van Roy et al;《Arthritis Research and Therapy》;第17卷(第1期);2 *
人补体片段C5a蛋白的可溶性表达、纯化及生物学活性检测;吕永强;《中国医药导刊》;第10卷(第10期);1-5 *

Also Published As

Publication number Publication date
IL271920A (en) 2020-02-27
US20250163138A1 (en) 2025-05-22
AU2025200313A1 (en) 2025-02-13
CO2020000369A2 (es) 2020-01-31
US11498960B2 (en) 2022-11-15
WO2019014360A1 (en) 2019-01-17
RU2020102910A3 (https=) 2021-12-02
AU2018301412A9 (en) 2025-08-07
KR20200026264A (ko) 2020-03-10
KR20250099285A (ko) 2025-07-01
JP2020532285A (ja) 2020-11-12
IL307197B1 (en) 2025-11-01
CN117327188A (zh) 2024-01-02
IL324119A (en) 2025-12-01
IL307197A (en) 2023-11-01
JP2025118590A (ja) 2025-08-13
CN111201246A (zh) 2020-05-26
CA3067247A1 (en) 2019-01-17
IL271920B2 (en) 2024-03-01
KR102806328B1 (ko) 2025-05-14
RU2020102910A (ru) 2021-08-11
EP3625265A1 (en) 2020-03-25
US20200399351A1 (en) 2020-12-24
BR112019028269A2 (pt) 2020-07-14
WO2019014360A8 (en) 2019-02-21
US20230235033A1 (en) 2023-07-27
JP2023120208A (ja) 2023-08-29
CN117327187A (zh) 2024-01-02
MX2024005945A (es) 2024-06-11
IL307197B2 (en) 2026-03-01
MX2024005946A (es) 2024-06-11
IL271920B1 (en) 2023-11-01
US12221473B2 (en) 2025-02-11
JP7684803B2 (ja) 2025-05-28
AU2018301412B2 (en) 2025-08-07
AU2025200303A1 (en) 2025-02-13
AU2018301412A1 (en) 2020-01-30
KR20250068795A (ko) 2025-05-16

Similar Documents

Publication Publication Date Title
CN111201246B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
KR102453227B1 (ko) 항-axl 길항성 항체
CN111744007B (zh) 一种抗tigit抗体药物组合物及其用途
US20240239878A1 (en) Binding molecule against dll3 and use thereof
WO2021155635A1 (zh) 抗cd3和cd123双特异性抗体及其用途
TWI801425B (zh) Il-5 抗體、其抗原結合片段及醫藥用途
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
US20250019457A1 (en) Trop2 antibodies
WO2024104431A1 (zh) 一种靶向FRα的抗体或其抗原结合片段及其应用
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
HK40106012A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40106013A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
JP7564882B2 (ja) Ａｒｅｇに対する抗体及びその用途
BR122025022103A2 (pt) Proteína de fusão, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira isolada, polipeptídeo manipulado, e método de preparação da proteína de fusão
WO2025171256A1 (en) Compositions and methods for treating malaria
WO2026008055A1 (zh) 抗kit抗体及其医药用途
JP2024535249A (ja) 合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027205

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Massachusetts

Patentee after: Alexion pharmaceutical Co.

Address before: Connecticut, USA

Patentee before: Alexion pharmaceutical Co.